Consequently, DCs that were cultured with the F127ZIF‐8AB680‐treated tumor CM displayed a marked increase in their ability to prime CD8+ T cell proliferation and activation, compared to the AB680‐treated groups or the CM control (Figure 7m–p). The gene discussed is CD8A; the disease is neoplasm.